News | August 16, 2021
IOL Chemicals and Pharma commissions Unit-10 for Rs 28.69 crores
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
The group has a total of 320 ANDA approvals
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Anti-malaria API facility will be operational in 15-18 months
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
The sensors have been tested for their different level of strains like micro and large scale motion monitoring and have potential applications in biomedical devices, skin electronics, and minimally invasive surgery
Company working on COVID vaccine INO 4800
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Subscribe To Our Newsletter & Stay Updated
